Impact of Germline Genetic Testing for Men with Prostate Cancer on Active Surveillance
Abstract
Active surveillance (AS) is now the standard-of-care treatment for men with low-risk prostate cancer. Although there is an association between the presence of germline pathogenic variants in certain DNA-damage repair genes and aggressive prostate cancer, whether presence of these mutations also lead to worse clinical outcomes in men on AS has not been systematically studied. We will conduct a prospective, single-arm clinical trial to examine how germline genetic testing affects men with prostate cancer on AS, both in terms of psychological outcomes and impact on clinical decision-making. We will also study the prevalence of germline pathogenic or likely pathogenic variants in DDR genes in this population and compare pathologic outcomes between germline DDR mutation carriers vs non-carriers. We will recruit600 participants over 3 years.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2022
- Accession Number
- AD1172219
Entities
People
- Maria I Carlo
Organizations
- Memorial Sloan Kettering Cancer Center